[Clinical bacteriological studies on cefotiam and cefsulodin in the field of otorhinolaryngology]. 1982

K Deguchi, and S Fukayama, and Y Nishimura

Clinical bacteriological studies on cefotiam and cefsulodin in the field of otorhinolaryngology were carried out and the following results were obtained. 1) Aerobic and anaerobic Gram-positive bacteria were dominantly isolated from the clinical materials sent to the center from the clinical institutes. 2) It was considered that Streptococcus pneumoniae, Haemophilus influenzae and beta-Streptococcus played an important role in the primary infections in the field of otorhinolaryngology. Staphylococcus aureus was also frequently isolated from the primary infections. Peptostreptococcus spp. was dominantly isolated from peritonsillar abscess. Gram-negative bacilli (GNB) were mainly isolated from the chronic secondary infections. Among GNB, Pseudomonas aeruginosa and Proteus spp. were more frequently isolated. Staphylococcus aureus was also constantly detected in the secondary infections together with GNB. Anaerobic bacteria were isolated from 20.1% of the patients with chronic otitis media and 27.1% of sinusitis. 3) Cefotiam showed potent antibacterial activities against most isolates of Gram-positive and Gram-negative bacteria. 4) Cefsulodin showed potent antibacterial activities against clinically isolated Pseudomonas aeruginosa. Staphylococcus aureus and beta-Streptococcus were also susceptible to cefsulodin.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010038 Otorhinolaryngologic Diseases Pathological processes of the ear, the nose, and the throat, also known as the ENT diseases. Otolaryngologic Diseases,ENT Diseases,Otolaryngological Diseases,Otorhinolaryngologic Disease,Otorhinolaryngological Disease,Disease, ENT,Disease, Otolaryngologic,Disease, Otolaryngological,Disease, Otorhinolaryngologic,Disease, Otorhinolaryngological,Diseases, ENT,Diseases, Otolaryngologic,Diseases, Otolaryngological,Diseases, Otorhinolaryngologic,Diseases, Otorhinolaryngological,ENT Disease,Otolaryngologic Disease,Otolaryngological Disease,Otorhinolaryngological Diseases
D002439 Cefotaxime Semisynthetic broad-spectrum cephalosporin. Benaxima,Biosint,Cefotaxim,Cefotaxime Sodium,Cefradil,Cephotaxim,Claforan,Fotexina,HR-756,Kendrick,Klaforan,Primafen,Ru-24756,Taporin,HR 756,HR756,Ru 24756,Ru24756,Sodium, Cefotaxime
D002441 Cefsulodin A pyridinium-substituted semisynthetic, broad-spectrum antibacterial used especially for Pseudomonas infections in debilitated patients. Abbott 46811,CGP-7174-E,Cefsulodin Monosodium Salt,Cefsulodin Sodium,Monaspor,Pyocefal,SCE-129,CGP 7174 E,CGP7174E,Monosodium Salt, Cefsulodin,SCE 129,SCE129,Sodium, Cefsulodin
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

K Deguchi, and S Fukayama, and Y Nishimura
October 1983, The Japanese journal of antibiotics,
K Deguchi, and S Fukayama, and Y Nishimura
December 1982, The Japanese journal of antibiotics,
K Deguchi, and S Fukayama, and Y Nishimura
November 1982, The Japanese journal of antibiotics,
K Deguchi, and S Fukayama, and Y Nishimura
November 1982, The Japanese journal of antibiotics,
K Deguchi, and S Fukayama, and Y Nishimura
November 1982, The Japanese journal of antibiotics,
K Deguchi, and S Fukayama, and Y Nishimura
November 1982, The Japanese journal of antibiotics,
K Deguchi, and S Fukayama, and Y Nishimura
November 1982, The Japanese journal of antibiotics,
K Deguchi, and S Fukayama, and Y Nishimura
December 1982, The Japanese journal of antibiotics,
K Deguchi, and S Fukayama, and Y Nishimura
December 1982, The Japanese journal of antibiotics,
K Deguchi, and S Fukayama, and Y Nishimura
December 1982, The Japanese journal of antibiotics,
Copied contents to your clipboard!